Our mission begins with the word cure. We recognize groundbreaking research will lead us toward the cures we seek. For more than 70 years, LLS support has been instrumental in the development of nearly every breakthrough in blood cancer treatment.
Our Research Grant portfolio contains programs that cover blood cancer research from the earliest phase of discovery science to translational research that goes from “Bench to Bedside” directly benefiting our patients. We also strongly believe that providing support to today's promising early-career scientists is fundamental to making sure that they will continue contributing to blood cancer research as tomorrow's leaders of the field.
We announce special, disease focused RFPs (requests for proposal) on a regular basis to accelerate research areas with high unmet need.
CURRENT FUNDING OPPORTUNITIES:
Equity in Access Letter of Intent due Sep 17, 2021
TRP Letter of Intent due Oct 29, 2021
CDP Eligibility submission due Nov 1, 2021
To move the needle further and faster, LLS forms partnerships with other organizations to fund meritorious blood cancer research together: